Study compares the effectiveness of maternal RSV vaccination versus infant nirsevimab against respiratory syncytial virus (RSV) infection and hospitalization in infants.
The policy directs the FDA not to take action against specialty pharmacies that sell a half-dozen wellness peptides, including BPC-157, TB-500 and KPV.